Myriad Genetics, Inc. (MYGN) and Cephalon, Inc. (CEPH) Enter Into Companion Diagnostic Agreement  
3/29/2012 10:09:55 AM

SALT LAKE CITY, March 28, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has signed an agreement with Cephalon Inc., a subsidiary of Teva Pharmaceutical Industries Ltd Company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase I/II clinical study.